Open AccessIntervention for Cognitive Reserve Enhancement in Delaying the Onset of Alzheimer’s Symptomatic Expression (INCREASE) Study: Results from a Randomized Controlled Study of Medication Therapy Management Targeting a Delay in Prodromal Dementia Symptom Progression
Author(s) -
Daniela C. Moga,
Erin L. Abner,
F.A. Schmitt,
Lynne Eckmann,
Mark Huffmyer,
Ashley I. Martinez,
Brooke F. Beech,
Rosmy George,
Riham H. El Khouli,
Doaa Ali,
Gregory A. Jicha
Publication year - 2022
Publication title -
the journal of prevention of alzheimer's disease/jpad
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.733
H-Index - 13
eISSN - 2426-0266
pISSN - 2274-5807
DOI - 10.14283/jpad.2022.55
Subject(s) - medicine , dementia , randomized controlled trial , intervention (counseling) , cognitive decline , physical therapy , cognition , disease , psychiatry
Cognitive reserve has been hypothesized as a mechanism to explain differences in individual risk for symptomatic expression of Alzheimer's Disease (AD). Inappropriate medications may diminish cognitive reserve, precipitating the transition from preclinical AD (pAD) to a symptomatic state. To date, there is limited data on the potential impact of medication optimization as a potential tool for slowing the symptomatic expression of AD.